UnknownNot applicableNCT05518331

The Safety and Efficacy Study of Avatrombopag Switch in TPO-RA Refractory AA

Studying Aplastic Anemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Principal Investigator
Liping Jing, Doctor
Anemia Treatment Center
Intervention
avatrombopag(drug)
Enrollment
39 enrolled
Eligibility
14 years · All sexes
Timeline
20222026

Study locations (1)

Collaborators

Peking University People's Hospital · Xiyuan Hospital of China Academy of Chinese Medical Sciences · Second Hospital of Shanxi Medical University · First Affiliated Hospital of Harbin Medical University · The First Hospital of Hebei Medical University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05518331 on ClinicalTrials.gov

Other trials for Aplastic Anemia

Additional recruiting or active studies for the same condition.

See all trials for Aplastic Anemia

← Back to all trials